DGX · Quest Diagnostics Inc

$245.00 +0.49 (+0.20%) At close · Aug 26

Market Cap

$26.99B

110.37M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue

$11.04B +11.8%

FY2025

Net Income

$992M +13.9%

FY2025

Gross Margin

38.5% +3.7pp

FY2020

Operating Margin

14.1% +0.5pp

FY2025

Diluted EPS

$8.75 +13.8%

FY2025

Operating Cash Flow

$1.89B +41.4%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow Adjusted All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2026 (G)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008	FY2007
Revenue	+3.7%	+3.2%	+3.9%	$11.95B – $12.05B	$11.56B	$11.04B	$9.87B^G	$9.25B^G	$9.88B^G	$10.79B	$9.44B	$7.73B	$7.53B	$7.4B	$7.21B	$7.49B	$7.44B	$7.15B	$7.38B	$7.39B	$7.26B	$7.46B	$7.25B	$6.7B
Interest & Dividend Income	+9.1%	+34.1%	+29.2%	—	$13M	$13M	$25M	$11M	$10M	$1M	$3M	$5M	$2M	$2M	$1M	$1M	$3M	—	—	—	—	—	—	—
Net Interest Income	—	—	—	—	-$256M	-$264M	-$201M	-$152M	-$138M	-$151M	-$163M	-$175M	-$167M	-$151M	-$143M	-$153M	-$164M	-$159M	—	—	—	—	—	—
Cost of Revenue	+4.5%	+4.9%	+4.7%	—	$7.73B	$7.37B	$6.63B	$6.2B	$6.45B	$6.58B	$5.8B	$5.04B	$4.93B	$4.72B	$4.62B	$4.66B	$4.64B	$4.33B	$4.37B	$4.36B	$4.28B	$4.32B	$4.26B	$3.97B
Gross Profit	+10.6%	+5.1%	+1.8%	—	—	—	—	—	—	—	$3.63B	$2.69B	$2.61B	$2.68B	$2.9B	$2.84B	$2.8B	$2.82B	$3.02B	$3.03B	$3.05B	$3.13B	—	—
Gross Margin	—	—	—	—	—	—	—	—	—	—	38.5%	34.8%	34.59%	36.25%	40.19%	37.85%	37.63%	39.46%	40.88%	40.98%	42.03%	42.03%	—	—
Selling, General & Administrative	+1.6%	+4.9%	+1.6%	—	$2.04B	$1.97B	$1.77B	$1.64B	$1.87B	$1.73B	$1.55B	$1.46B	$1.42B	$1.44B	$1.38B	$1.68B	$1.73B	$1.7B	$1.75B	$1.74B	$1.66B	$1.75B	$1.74B	$1.61B
Amortization of Intangibles	+8.7%	+8.4%	+6.6%	—	$151M	$154M	$127M	$108M	$120M	$103M	$103M	$96M	$90M	$74M	$72M	$81M	$94M	$79M	$75M	$61M	$33.11M	$37.06M	$37.29M	$27.9M
Depreciation & Amortization	+9.3%	+9.6%	+6.5%	—	$580M	$570M	$493M	$439M	$437M	$408M	$361M	$329M	$309M	$270M	$249M	$304M	$314M	$283M	$287M	$281M	$253.96M	$256.69M	$264.59M	$237.88M
Restructuring Charges	—	+12.9%	—	—	—	—	—	—	$55M	$13M	$14M	-$3M	$49M	$30M	$11M	$39M	$43M	$75M	—	—	—	—	—	—
Total Costs & Expenses	+3.9%	+4.9%	+4.5%	—	$9.93B	$9.48B	$8.53B	$7.99B	$8.46B	$8.41B	$7.47B	$6.5B	$6.43B	$6.24B	$5.94B	$6.09B	$6.45B	$5.67B	$6.18B	$6.41B	$5.98B	$6.1B	$6.03B	$5.61B
Operating Income	+2.9%	-4.6%	+1.1%	—	$1.63B	$1.56B	$1.35B	$1.26B	$1.43B	$2.38B	$1.97B	$1.23B	$1.1B	$1.17B	$1.28B	$1.4B	$983M	$1.48B	$1.2B	$987M	$1.28B	$1.36B	$1.22B	$1.09B
Operating Margin	—	—	—	—	—	14.1%	13.63%	13.64%	14.45%	22.07%	20.89%	15.93%	14.62%	15.74%	17.7%	18.67%	13.22%	20.64%	16.27%	13.35%	17.68%	18.23%	16.86%	16.28%
EBITDA	+4.5%	-1.8%	+2.2%	—	$2.21B	$2.13B	$1.84B	$1.7B	$1.87B	$2.79B	$2.33B	$1.56B	$1.41B	$1.44B	$1.53B	$1.7B	$1.3B	$1.76B	$1.49B	$1.27B	$1.54B	$1.62B	$1.49B	$1.33B
Interest Expense	+23.2%	+10.8%	+6.0%	—	$269M	$277M	$226M	$163M	$148M	$152M	$166M	$180M	$169M	$153M	$144M	$154M	$167M	—	—	$173.35M	$147.5M	$146.59M	-$185.48M	—
Interest Income	-21.5%	—	—	—	$3.12M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$2.77M	$1.41M	$2.52M	$5.71M	—
Other Non-Operating Income	—	—	—	—	-$226M	-$238M	-$171M	-$132M	-$193M	$218M	-$87M	-$155M	-$175M	-$135M	-$191M	-$296M	-$160M	-$151M	-$133M	-$138M	-$108.6M	-$131.18M	-$171.72M	-$152.42M
Equity in Earnings of Unconsolidated Entities	-1.5%	-10.9%	+6.2%	—	$29M	$42M	$19M	$26M	$44M	$78M	$75M	$57M	$44M	$35M	$39M	$23M	$26M	$24M	$26M	$29M	$29.56M	$33.21M	$29.74M	$26.97M
Investment Income (Loss)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$3M	$3.3M	$6M	-$9.9M	—
Pretax Income	+2.2%	-6.9%	+1.8%	—	$1.4B	$1.32B	$1.18B	$1.13B	$1.24B	$2.6B	$1.88B	$1.08B	$926M	$1.03B	$1.09B	$1.1B	$823M	$1.32B	—	$856.23M	$1.18B	$1.23B	$1.05B	—
Income Tax	+6.0%	-7.4%	-1.7%	—	$320M	$314M	$273M	$248M	$264M	$597M	$460M	$247M	$182M	$241M	$429M	$373M	$262M	$500M	$402M	$355M	$430.13M	$460.47M	$386.77M	$358.57M
Net Income	+1.6%	-7.1%	+3.4%	—	$1.06B	$992M	$871M	$854M	$946M	$2B	$1.43B	$858M	$736M	$772M	$645M	$709M	$556M	$849M	$556M	$471M	$720.89M	$729.11M	$581.49M	$339.94M
Net Margin	—	—	—	—	—	8.99%	8.82%	9.23%	9.57%	18.49%	15.16%	11.11%	9.77%	10.43%	8.94%	9.46%	7.48%	11.88%	7.53%	6.37%	9.93%	9.78%	8.02%	5.07%
Net Income Attributable to Noncontrolling Interests	-7.8%	-4.5%	+2.1%	—	$51M	$54M	$50M	$54M	$69M	$85M	$68M	$48M	$52M	$52M	$51M	$44M	$36M	$34M	$36M	$35M	$36.12M	$37.11M	$31.71M	$26.51M
Net Income Available to Common Stockholders	+1.3%	—	—	—	—	—	—	—	—	—	—	—	$733M	$769M	$642M	$706M	$549M	—	—	—	—	—	—	—
Comprehensive Income	+3.9%	-6.2%	+4.2%	—	$1.02B	$1.05B	$797M	$861M	$939M	$2B	$1.45B	$878M	$727M	$796M	$611M	$698M	$537M	$827M	$578M	$452M	$752.48M	—	—	—
EPS (Basic) USD/shares	+3.1%	-3.5%	+6.1%	—	—	$8.87	$7.78	$7.59	$8.10	$15.85	$10.62	$6.36	$5.39	$5.63	$4.58	$4.92	$3.83	$5.58	$3.49	$2.95	$4.08	$3.91	$2.99	$1.76
EPS (Diluted) USD/shares	+3.2%	-3.5%	+6.0%	$11.05 – $11.25*	—	$8.75^G	$7.69^G	$7.49^G	$7.97^G	$15.55	$10.47	$6.28	$5.29	$5.50	$4.51	$4.87	$3.81	$5.54	$3.46	$2.92	$4.05	$3.87	$2.96	$1.74
Shares Outstanding (Basic Avg) shares	-1.5%	-3.7%	-2.6%	—	—	111M	111M	112M	116M	125M	134M	134M	136M	137M	140M	144M	145M	152M	159M	159M	175.68M	185.95M	194.28M	—
Shares Outstanding (Diluted Avg) shares	-1.4%	-3.6%	-2.5%	—	—	113M	113M	113M	118M	128M	136M	136M	139M	140M	142M	145M	145M	153M	160M	160M	177.32M	187.8M	195.96M	—

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $10.72B in buybacks, $3.99B in dividends.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

2.77×

Peer median 6.13×

EV/EBIT

19.63×

Peer median 39.66×

P/E (TTM)

25.96×

Peer median 34.28×

Peer medians compare against the 23 similar-size Diagnostics & Research companies (of 48 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Diagnostic Information Services Business	$10,785,000,000	$9,614,000,000	$8,976,000,000	$9,609,000,000	$10,494,000,000	$9,139,000,000	$7,405,000,000	$7,204,000,000
All Other Segments	$250,000,000	$258,000,000	$276,000,000	$274,000,000	$294,000,000	$298,000,000	$321,000,000	$327,000,000

By Product & Service (USD)

Component	FY2021	FY2020	FY2019	FY2018	FY2017
Routine Clinical Testing Services	$4,293,000,000	$3,836,000,000	$4,206,000,000	$4,217,000,000	$4,006,000,000
Genebased And Esoteric Testing Services	$2,878,000,000	$2,098,000,000	$2,620,000,000	$2,409,000,000	$2,449,000,000
COVID19 Testing Services	$2,770,000,000	$2,723,000,000	$0	$0	—
Anatomic Pathology Testing Services	$553,000,000	$482,000,000	$579,000,000	$578,000,000	$612,000,000
All Other Services	$294,000,000	$298,000,000	$321,000,000	$327,000,000	$335,000,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Diagnostic Information Services Business	$1,829,000,000	$1,630,000,000	$1,547,000,000	$1,704,000,000	$2,646,000,000	$2,201,000,000	$1,298,000,000	$1,235,000,000
All Other Segments	$32,000,000	$33,000,000	$34,000,000	$20,000,000	$29,000,000	$39,000,000	$42,000,000	$47,000,000
Corporate	-$305,000,000	-$317,000,000	-$319,000,000	-$296,000,000	-$294,000,000	-$269,000,000	-$109,000,000	-$181,000,000

Operating Margin by Segment (%)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Diagnostic Information Services Business	17%	17%	17.2%	17.7%	25.2%	24.1%	17.5%	17.1%
All Other Segments	12.8%	12.8%	12.3%	7.3%	9.9%	13.1%	13.1%	14.4%

Key facts CIK 1022079 CUSIP 74834L100 13F (30d) 785 filings 781 filers Visit website Investor relations